Trial watch: intratumoral immunotherapy - Sorbonne Université
Article Dans Une Revue OncoImmunology Année : 2021

Trial watch: intratumoral immunotherapy

Juliette Humeau
Julie Le Naour
Guido Kroemer
Jonathan G Pol

Résumé

While chemotherapy and radiotherapy remain the first-line approaches for the management of most unresectable tumors, immunotherapy has emerged in the past two decades as a game-changing treatment, notably with the clinical success of immune checkpoint inhibitors. Immunotherapies aim at (re) activating anticancer immune responses which occur in two main steps: (1) the activation and expansion of tumor-specific T cells following cross-presentation of tumor antigens by specialized myeloid cells (priming phase); and (2) the immunological clearance of malignant cells by these antitumor T lymphocytes (effector phase). Therapeutic vaccines, adjuvants, monoclonal antibodies, cytokines, immunogenic cell death-inducing agents including oncolytic viruses, anthracycline-based chemotherapy and radiotherapy, as well as adoptive cell transfer, all act at different levels of this cascade to (re)instate cancer immunosurveillance. Intratumoral delivery of these immunotherapeutics is being tested in clinical trials to promote superior antitumor immune activity in the context of limited systemic toxicity.
Fichier principal
Vignette du fichier
Trial watch intratumoral immunotherapy.pdf (1.77 Mo) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-03405467 , version 1 (27-10-2021)

Identifiants

Citer

Juliette Humeau, Julie Le Naour, Lorenzo Galluzzi, Guido Kroemer, Jonathan G Pol. Trial watch: intratumoral immunotherapy. OncoImmunology, 2021, 10 (1), ⟨10.1080/2162402x.2021.1984677⟩. ⟨hal-03405467⟩
46 Consultations
190 Téléchargements

Altmetric

Partager

More